Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 22Recruiting 8Active not recruiting 5Unknown 2Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 10NETWORK 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Neoplasms 473Carcinoma, Non-Small-Cell Lung 447Breast Neoplasms 331Neoplasm Metastasis 242Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 148Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 123Carcinoma, Renal Cell 112Squamous Cell Carcinoma of Head and Neck 110Leukemia, Lymphocytic, Chronic, B-Cell 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 87Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 74Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Vulvar Neoplasms × Clear all
NCT05949632 2025-08-03

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Terminated
5 enrolled
GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT00669422 2012-10-05

ChemoFx® PRO - A Post-Market Data Collection Study

Precision Therapeutics

Terminated
2,756 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Hypersensitivity, Ovarian Neoplasms, Recurrence, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡